Study Finds pVADs are Cost-Effective for High-Risk PCI

In the era of increasing healthcare costs, the cost-effectiveness of traditional versus emerging technologies is an ongoing consideration when evaluating long-term outcomes. A meta-analysis derived from six studies (Maini et al. 2014) determined that percutaneous ventricular assist devices (pVADs), particularly the Impella 2.5™ heart pump, were cost effective in the setting of high-risk PCI, when compared to the IABP.  “The incremental cost-effectiveness ratio of Impella 2.5 was below the standard willingness-to-pay threshold.”

Of the studies reviewed, Gregory et al. 2013 and Roos et al. 2013 assessed the economic benefit of the Impella 2.5 alone in high-risk PCI patients, as shown below:

Studies Evaluating the Cost Effectiveness of the Impella 2.5 device for High-Risk PCI*

^* Table adapted from Tables 1 and 2, Maini et al. 2014.

^**NR=not reported

The authors concluded the cost reductions associated with the Impella 2.5 makes it “a high-value technology.”

To Learn More:

1. Read the original article by Maini et al. 2014
2. Read the original article by Gregory et al. 2013
3. Read the original article by Roos et al. 2013
4. Learn more about the use of Impella 2.5 for PCI

To learn more about the Impella^® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: www.protectedpci.com/indications-use-safety-information/